Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS MAY ISSUE PUBLISHED
  • MAY 2021 Issue has been successfully launched on 1 May 2021.

Abstract

PREVENTIVE EFFECT OF VILDAGLIPTIN AND FENOFIBRATE ON DIABETIC NEUROPATHY IN WISTAR RATS

Savita D. Patil*, Nilesh N. Chavan*, Kishor V. Pachpute, Amit D. Patil,Vineet S. Zope, Mayur A. Chaudhari, Prabodh V. Sapkale

ABSTRACT

Objectives: Fenofibrate (PPARĪ±) a lipid lowering drug and also Fenofibrate intervention and event lowering in diabetes (FIELD) effect and vildagliptin a new antidiabetic drug in type 2 diabetic patients, the present study aims to evaluate the preventive effect of vildgliptin and fenofibrate on diabetic neuropathy. Materials and Methods: The rats were subjected to severe diabetic treatment with fenofibrate and vildagliptin and their combination the change in diabetic condition was assessed by various biochemical plasma parameters like glucose, cholesterol, triglycerides, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), pharmacological parameters like hot plate test, tail flick test, randall selitto test, cold allodynia and histopathological studies. Results: The combination effect of vildagliptin with fenofibrate shows improvement in diabetes by reducing the plasma glucose level and also improve in lipid level by significantly reducing the TG, LDL, VLDL cholesterol and recovered by HDL cholesterol, and diabetic neuropathy are also prevented which is supported by significantly evaluation in pharmacological parameters and histopathological reports. Conclusion : The present study shows that vildgliptin decreased plasma glucose and fenofibrate decreased lipid profile and hence it shows that prevents the diabetic neuropathy in alloxan induced diabetic rats.

Keywords: Vildagliptin, Fenofibrate, Alloxan, Diabetic Neuropathy.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More